Technetium Tc-99m Sestamibi SPECT / CT Imaging in Treating Patients with Kidney Cancer

Status: Active

Description

This phase I trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography (SPECT) / computed tomography (CT) imaging works in treating patients with kidney cancer. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT / CT, may help find and diagnose kidney cancer.

Eligibility Criteria

Inclusion Criteria

  • MAIN STUDY COHORT INCLUSION CRITERIA: Presence of a solid enhancing cT1 renal mass (i.e. =< 7 cm) diagnosed on cross-sectional imaging
  • MAIN STUDY COHORT INCLUSION CRITERIA: Scheduled to undergo surgery with either partial or radical nephrectomy
  • RENAL CELL CARCINOMA (RCC) COHORT INCLUSION CRITERIA: History of histologically-proven locally advanced or metastatic (cT2a-T4NanyMany) chromophobe RCC

Exclusion Criteria

  • MAIN STUDY COHORT EXCLUSION CRITERIA: Pregnancy (as determined by point of care test administered in accordance with the policies of the Department of Nuclear Medicine)
  • MAIN STUDY COHORT EXCLUSION CRITERIA: Evidence of nodal or distant metastases
  • MAIN STUDY COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibi
  • RENAL CELL CARCINOMA (RCC) COHORT EXCLUSION CRITERIA: Pregnancy (as determined by point of care test administered in accordance with the policies of the Department of Nuclear Medicine)
  • RENAL CELL CARCINOMA (RCC) COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibi

Locations & Contacts

Maryland

Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: Active
Contact: Mohamad E. Allaf
Phone: 410-502-7710

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To investigate the utility of technetium Tc-99m sestamibi (99mTc-sestamibi) single-photon emission computed tomography/x-ray computed tomography (SPECT/CT) imaging for the preoperative diagnosis of renal oncocytoma.

OUTLINE:

Within 4 weeks of surgery, patients receive technetium Tc-99m sestamibi injection and then undergo SPECT/CT over 1 hour.

Trial Phase & Type

Trial Phase

Phase I

Trial Type

Treatment

Lead Organization

Lead Organization
Johns Hopkins University / Sidney Kimmel Cancer Center

Principal Investigator
Mohamad E. Allaf

Trial IDs

Primary ID J1412
Secondary IDs NCI-2017-01500, CRMS-58909, IRB00027784
Clinicaltrials.gov ID NCT02160925